CareDx (CDNA) Cash & Equivalents (2013 - 2026)

CareDx (CDNA) has 14 years of Cash & Equivalents data on file, last reported at $77.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 12.19% year-over-year to $77.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.9 million (down 12.19% YoY) and the FY2025 annual result came in at $65.4 million, down 42.95% from the prior year.
• Cash & Equivalents rose to $77.9 million in Q1 2026 per CDNA's latest filing, from $65.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $171.9 million in Q1 2022, with the low at $65.4 million in Q4 2025.
• Average Cash & Equivalents over 5 years is $95.5 million, with a median of $88.7 million recorded in 2025.
• Year-over-year, Cash & Equivalents sank 76.5% in 2022 and soared 39.53% in 2024.
• CareDx's Cash & Equivalents stood at $89.9 million in 2022, then retreated by 8.59% to $82.2 million in 2023, then soared by 39.53% to $114.7 million in 2024, then plunged by 42.95% to $65.4 million in 2025, then grew by 19.1% to $77.9 million in 2026.
• Business Quant data shows CDNA's Cash & Equivalents at $77.9 million in Q1 2026, $65.4 million in Q4 2025, and $91.4 million in Q3 2025.